Detalhe da pesquisa
1.
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial.
Blood
; 121(9): 1517-23, 2013 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23297129